A Phase 1 Study to Assess the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel
Latest Information Update: 06 Apr 2026
At a glance
- Drugs ABBV 722 (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Idiopathic pulmonary fibrosis; Systemic scleroderma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 06 Apr 2026 New trial record